Vanda Q3 2022 revenue $65.3M (-7% YoY); net income $3.3M; narrows full-year guidance

Vanda Pharmaceuticals Inc.

2022-Q3 EPS reported -$0.01 revenue$189,900,000

Q3 total revenues $65.3M, down 7% from $70.1M; HETLIOZ sales $41.3M (-9%), Fanapt $24.0M (-2%).
Net income $3.3M ($0.06 diluted EPS) vs $7.8M ($0.14) a year ago; first nine months net loss $0.6M.
Full-year 2022 revenue guidance narrowed to $240-270M (from $240-280M); year-end cash forecast >$450M.
Cash, cash equivalents and marketable securities $454.8M as of Sept 30, up $48.8M YoY.
Pipeline: sNDA for HETLIOZ in insomnia expected by end-2022; NDA for tradipitant in gastroparesis expected H1 2023; Fanapt bipolar Phase III fully enrolled, results by end-2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vanda Pharmaceuticals Inc. reported third quarter ended September 30, 2022 results: net income $3.3 million, EPS $0.06.

Period: third quarter ended September 30, 2022
Net income: $3.3 million
EPS: $0.06
Result: reported results

Exact text from the filing

Net income was $3.3 million in the third quarter of 2022 compared to net income of $7.8 million in the third quarter of 2021. Diluted net income per share was $0.06 in the third quarter of 2022 compared to diluted net income per share of $0.14 in the third quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vanda Pharmaceuticals Inc. reported full year 2022 results: revenue $240 to $270 million. Guidance lowered.

Period: full year 2022
Revenue: $240 to $270 million
Guidance: lowered
Result: guidance update

Exact text from the filing

Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022 : Full Year 2022 Financial Objectives Revised Full Year 2022 Guidance Prior Full Year 2022 Guidance Total revenues $240 to $270 million $240 to $280 million HETLIOZ ® net product sales $150 to $170 million $150 to $180 million Fanapt ® net product sales $90 to $100 million $90 to $100 million Year-end 2022 Cash Greater than $450 million Greater than $440 million

View on SEC.gov

Browse all earnings releases →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.